Announcements Trials
Browse Landscape

Phase

Phase 2 3

Status

Recruiting 2Active not recruiting 1

Sponsor Class

NIH 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Endocrine 3Sarcoma 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Carcinoma, Renal Cell 46Carcinoma, Hepatocellular 13Osteosarcoma 8Neoplasms 8Sarcoma 7Prostatic Neoplasms 7Neoplasm Metastasis 7Colorectal Neoplasms 7Sarcoma, Ewing 6Neuroendocrine Tumors 6Kidney Neoplasms 6Clear-cell metastatic renal cell carcinoma 6Carcinoma, Non-Small-Cell Lung 6Thyroid Neoplasms 4Carcinoma, Transitional Cell 4Carcinoma, Medullary 4Carcinoma 4Brain Neoplasms 4Urinary Bladder Neoplasms 3Urethral Neoplasms 3Ovarian Neoplasms 3Melanoma 3Endometrial Neoplasms 3Adrenocortical Carcinoma 3Wilms Tumor 2Urogenital Neoplasms 2Ureteral Neoplasms 2Triple Negative Breast Neoplasms 2Thyroid Cancer, Papillary 2Stomach Neoplasms 2

Interventions

pembrolizumab 5Specimen Handling 4Magnetic Resonance Spectroscopy 4cabozantinib 3Nivolumab 3cemiplimab 2Ipilimumab 2sodium thiosulfate 1relacorilant 1lenvatinib 1fludarabine phosphate 1dostarlimab 1Radiation 1Mitotane 1Interleukin-13 1Fluorodeoxyglucose F18 1Floxuridine 1E-7386 1Drug Therapy 1Dexamethasone 1Cytoreduction Surgical Procedures 1Cyclophosphamide 1Cisplatin 1CTLA-4 Antigen 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Adrenocortical Carcinoma × cabozantinib × 1 year × Clear all
NCT02867592 2026-05-27

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

National Cancer Institute (NCI)

Phase 2 Active not recruiting
109 enrolled 24 charts
CNSEndocrineGastrointestinalGenitourinarySarcoma

Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Wilms Tumor, Rhabdomyosarcoma, Sarcoma, Sarcoma, Ewing, Osteosarcoma, Central Nervous System Neoplasms, Hepatoblastoma, Sarcoma, Clear Cell, Sarcoma, Alveolar Soft Part, Adrenocortical Carcinoma, Carcinoma, Medullary

NCT06900595 2026-05-22

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

National Cancer Institute (NCI)

Phase 2 Recruiting
48 enrolled
Endocrine

Adrenocortical Carcinoma

NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Emory University

Phase 2 Recruiting
21 enrolled
Endocrine

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡